Danish Medicines Council releases recommendations – mixed bag for Sanofi and BMS

Eight applications have been processed during the Danish Medicines Council’s March meeting, including submissions on indication expansions from Sanofi and Bristol Myers Squibb, both of which received both good and less-than-uplifting recommendations.

Photo: Stine Rasmussen/Ritzau Scanpix

On Wednesday last week, pharmaceutical firms Sanofi and Bristol Myers Squibb received a mixed bag of recommendations from Danish Medicines Council.

At its monthly meeting, the council’s members turned their thumbs down for Sanofi, which had applied to have its blockbuster drug Dupixent (dupilumab) approved in the country as a treatment for chronic rhinosinusitis with nasal polyps.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs